Evidence map›Paper›PMID 37062062›Full record

ReviewCurrent medicinal chemistry2024

Research Progress of Chitosan-based Multifunctional Nanoparticles in Cancer Targeted Therapy.

Chunmei Lai, Simin Lin, Wei Liu, Yanqiao Jin

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chunmei LaiCollege of Materials Science and Engineering, Fuzhou University, Fuzhou, 350108, China.
Simin LinCollege of Materials Science and Engineering, Fuzhou University, Fuzhou, 350108, China.
Wei LiuFujian College Association Instrumental Analysis Center of Fuzhou University, Fuzhou University, Fuzhou, 350108, China.
Yanqiao JinCollege of Materials Science and Engineering, Fuzhou University, Fuzhou, 350108, China.
Fuzhou University · CN

Funding

National Natural Science Foundation of China 51503041
6 · The paper itself

Abstract

Conventional tumor therapeutic modalities, such as radiotherapy, chemotherapy, and surgery, involve low tumor inhibition efficiency, non-targeted drug delivery, and side effects. The development of novel and practical nano-drug delivery systems (DDSs) for targeted tumor therapy has become particularly important. Among various bioactive nanoparticles, chitosan is considered a suitable candidate for drug delivery due to its nontoxicity, good biocompatibility, and biodegradability. The amino and hydroxyl groups of chitosan endow it with the diverse function of chemical modification, thereby improving its physical and biological properties to meet the requirements of advanced biomedical applications. Therefore, it is necessary to review the property and applications of chitosan- based materials in biomedicine. In this review, the characteristics of chitosan related to its applications are first introduced, and then the preparation and modification of chitosan-based nanoparticles, including the function tailoring of chitosan-modified nanoparticles, are demonstrated and discussed. Finally, the opportunities and challenges of chitosan- based nanomaterials in this emerging field are proposed from the perspective of the rational and systematic design for the biomedicine field.

Indexed as

Antineoplastic AgentsChitosanNeoplasmsAnimalsDrug CarriersDrug Delivery SystemsHumansMultifunctional NanoparticlesNanoparticlesAntineoplastic AgentsChitosanDrug Carriersbiocompatibility.cancer treatmentChitosannano-drug delivery systems (DDSs)nanoparticlestargeted delivery

Identifiers

PMID37062062
OpenAlexW4365998086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.